Follow us on Twitter
twitter icon@FreshPatents

Immunotherapy patents

Bulk PDF Downloads
      

This page is updated frequently with new Immunotherapy-related patent applications.




 Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system patent thumbnailnew patent Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
The present invention relates to methods of developing genetically engineered, preferably non-alloreactive t-cells for immunotherapy. This method involves the use of rna-guided endonucleases, in particular cas9/crispr system, to specifically target a selection of key genes in t-cells.
Cellectis


 Low molecular weight immune-modulators as adjuvants for specific immunotherapy patent thumbnailnew patent Low molecular weight immune-modulators as adjuvants for specific immunotherapy
The invention relates to a pharmaceutical composition for local modulation of t cell and b cell responses at the site of allergen or antigen presentation, made of one or more preparations comprising one or more antigens or allergens, and a therapeutically effective dose of two or more low molecular weight immune modulators selected from four groups of tolerance-inducing therapeutics comprising inhibitors of complement-mediated functions, inhibitors of tumor necrosis factor receptor 1 (tnfr1)-mediated functions, inhibitors of interleukin 4- and interleukin 13-mediated functions, and therapeutic agents suitable for vitamin d3 supplementation wherein preferably two or more low molecular weight immune modulators and one or more antigens or allergens are coated or adsorbed on or embedded in a matrix, wherein the matrix is selected as to enable sustained release of one or more antigens or allergens and two or more immune modulators for the treatment of t cell-mediated diseases.. .
Helmholtz Zentrum MÜnchen Forschungszentrum FÜr Gesundheit Und Umwelt Gmbh


 Tetanus toxoid and ccl3 improve dc vaccines patent thumbnailnew patent Tetanus toxoid and ccl3 improve dc vaccines
Pre-conditioning a vaccine site with a potent recall antigen such as tetanus/diphtheria (td) toxoid can significantly improve the lymph node homing and efficacy of tumor antigen-specific dc vaccines. Patients given td had enhanced dc migration bilaterally and significantly improved survival.
Duke University


 Yeast-based immunotherapy for chordoma patent thumbnailnew patent Yeast-based immunotherapy for chordoma
One embodiment of the invention relates to a method to treat chordoma in an individual who has chordoma. The method includes the step of administering to an individual who has chordoma, an immunotherapeutic composition comprising: (a) a yeast vehicle; and (b) a cancer antigen comprising at least one brachyury antigen.
The United States Of America, As Represented By The Secretary, Department Of Health And


 Vmp-like sequences of pathogenic borrelia patent thumbnailVmp-like sequences of pathogenic borrelia
The present invention relates to dna sequences encoding vmp-like polypeptides of pathogenic borreliae, the use of the dna sequences in recombinant vectors to express polypeptides, the encoded amino acid sequences, application of the dna and amino acid sequences to the production of polypeptides as antigens for immunoprophylaxis, immunotherapy, and immunodiagnosis. Also disclosed are the use of the nucleic acid sequences as probes or primers for the detection of organisms causing lyme disease, relapsing fever, or related disorders, and kits designed to facilitate methods of using the described polypeptides, dna segments and antibodies..
Board Of Regents, The University Of Texas System


 Costimulatory b7-h1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target patent thumbnailCostimulatory b7-h1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target
The invention features methods of diagnosis by assessing b7-h1 expression in a tissue from a subject that has, or is suspected of having, cancer, methods of treatment with agents that interfere with b7-h1-receptor interaction, methods of selecting candidate subjects likely to benefit from cancer immunotherapy, and methods of inhibiting expression of b7-h1.. .
Mayo Foundation For Medical Education And Research


 Ctl peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof patent thumbnailCtl peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
The present invention relates to ctl peptide epitopes, high-throughput methods for their identification, and their uses. In particular, the present invention relates to peptide epitopes for cancer immunotherapy and hepatitis c virus vaccines.
Oslo Universitetssykehus Hf


 Methods for treating newly diagnosed multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with second active agents patent thumbnailMethods for treating newly diagnosed multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with second active agents
Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient.
Celgene Corporation


 Costimulatory b7-h1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target patent thumbnailCostimulatory b7-h1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target
The invention features methods of diagnosis by assessing b7-h1 expression in a tissue from a subject that has, or is suspected of having, cancer, methods of treatment with agents that interfere with b7-h1-receptor interaction, methods of selecting candidate subjects likely to benefit from cancer immunotherapy, and methods of inhibiting expression of b7-h1.. .
Mayo Foundation For Medical Education And Research


 Polyclonal gamma delta t cells for immunotherapy patent thumbnailPolyclonal gamma delta t cells for immunotherapy
Provided herein is a method of expanding clinically-relevant quantities of polyclonal γδ t cells that have anti-tumor, anti-viral, and anti-bacterial reactivity. Polyclonal γδ t cells can target a variety of tumors, including solid tumors as well as other conditions, such as viral and bacterial infections..
Board Of Regents, The University Of Texas System


Antibodies against phosphorylcholine in combination therapy with biologic agents


Antibodies against pc, pc conjugate or bioactive components and/or fragments thereof for use in combination therapy with one or more biologic agents and/or stem cells are disclosed, as well as compositions comprising the antibodies in combination with one or more biologic agents and/or stem cells. Also disclosed are pc conjugates, pc or bioactive components and/or parts/fragments thereof for use in activation immunotherapy prior to or in combination with treatment with biologic agents and/or stem cells for curing, treating, preventing, and/or reducing the risk of developing auto-immune diseases, chronic inflammatory diseases, and cancer diseases, as well as compositions comprising them in combination with biologic agents and/or stem cells..
Medirista Biotechnologies Ab


Antibodies against phosphorylcholine in combination therapy with biologic agents


Antibodies against pc, pc conjugate or bioactive components and/or fragments thereof for use in combination therapy with one or more biologic agents and/or stem cells are disclosed, as well as compositions comprising the antibodies in combination with one or more biologic agents and/or stem cells. Also disclosed are pc conjugates, pc or bioactive components and/or parts/fragments thereof for use in activation immunotherapy prior to or in combination with treatment with biologic agents and/or stem cells for curing, treating, preventing, and/or reducing the risk of developing auto-immune diseases, chronic inflammatory diseases, and cancer diseases, as well as compositions comprising them in combination with biologic agents and/or stem cells..
Medirista Biotechnologies Ab


Dna vaccine for use in pancreatic cancer patients


The present invention relates to an attenuated mutant strain of salmonella comprising a recombinant dna molecule encoding a vegf receptor protein. In particular, the present invention relate to the use of said attenuated mutant strain of salmonella in cancer immunotherapy..
Vaximm Ag


Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers


The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh


In vivo individualized systemic immunotherapeutic


The invention provides an in vivo individualized systemic immunotherapeutic method and device. The method includes, in a non-sequential manner: (1) increasing release amount of tumor antigens at a tumor site; (2) at the tumor site, increasing level of proteins capable of adhering to and/or wrapping the tumor antigens; (3) at the tumor site, increasing level of dedicated antigen-presenting cells involved in immunity, and establishing, between the dedicated antigen-presenting cells and immune effector cells, a close connection capable of activating the immune effector cells; and (4) at the tumor site, increasing level and improving function of the immune effector cells.
Hangzhou Converd Co., Ltd.


Costimulatory b7-h1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target


The invention features methods of diagnosis by assessing b7-h1 expression in a tissue from a subject that has, or is suspected of having, cancer, methods of treatment with agents that interfere with b7-h1-receptor interaction, methods of selecting candidate subjects likely to benefit from cancer immunotherapy, and methods of inhibiting expression of b7-h1.. .
Mayo Foundation For Medical Education And Research


Combination immunotherapy for the treatment of cancer


Agonists to icos in combination with a blocking agent to a t cell inhibitory receptor (e.g., ctla-4, pd-1, etc.) are demonstrated herein to be useful for the treatment of tumors.. .
Memorial Sloan-kettering Cancer Center


Human anti-alpha-synuclein antibodies


Provided are human alpha-synuclein-specific autoantibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for α-synuclein are also disclosed.
University Of Zurich


Human monoclonal antibodies


The present invention relates, in general, to hiv-1-reactive antibodies and, in at least certain specific embodiments, to broadly neutralizing antibodies (bnabs) (and fragments and derivatives thereof) and to compositions comprising same. The invention further relates to methods of using such bnabs (and fragments and derivatives thereof) and compositions in immunotherapy regimens (e.g., passive immunotherapy regimens).
Duke University


Order a batch download of a huge number of patent PDFs. Bulk PDF Downloads This is a premium service.

Ablative immunotherapy


The disclosure herein relates generally to immunotherapy and, more specifically, to the use of immunotherapy for treating tumors and pathogen infected tissues. The immunotherapy relates to first priming patients with allogeneic cells designed to be rejected by a th1 mediated mechanism, then inducing in situ necrosis or apoptosis in a tumor or pathogen infected lesion.
Immunovative Therapies Ltd.


Targeting immunotherapy for amyloidosis


Disclosed are methods and compositions for targeting antibodies to amyloid deposits. For example, amyloid-reactive peptides that bind amyloid deposits are administered to a subject.
University Of Tennessee Research Foundation


Fusion molecule based on novel taa variant


This invention provides novel carbonic anhydrase (caix) nucleic acid and peptide sequences, as well as related methods and compositions, including anti-cancer immunogenic agent(s) (e.g. Vaccines and chimeric molecules) that elicit an immune response specifically directed against cancer cells expressing a caix antigenic marker.
The Regents Of The University Of California


Adoptive cell transfer methods


Methods and compositions are presented for mobilizing hematopoietic stem cells (hsc) and for mobilizing t lymphocytes from the bone marrow and other compartments; use of the mobilized hscs for hsc transplantation and mobilized t lymphocytes for t cell immunotherapy; for enhancing engraftment of transplanted hscs and transferred t cells; and for enhancing recovery of hematopoietic system function following hsc transplantation or for enhancing engraftment and/or persistence of t cells following transfer for t cell immunotherapy.. .
Cantex Pharmaceuticals, Inc.


Patient-specific immunotherapy for treating heterogeneous tumors


In the field of therapy, specifically patient-specific immune therapy for cancer, improved therapeutic modalities are provided for. The identity and dosage of the administered anti-tumor antibodies is determined and dynamically adjusted to the individual patient's condition, disease and/or treatment progression, thus providing anti-cancer treatment which may be particularly advantageous for the treatment of heterogeneous tumors..
Suri Technologies Ltd.


Factors


A method for determining a prognosis for benefit for a cancer patient receiving immunotherapy treatment involving (a) measuring a level of platelets and haemoglobin in a sample from the cancer patient, and (b) comparing the level of platelets in the sample to a reference level of platelets and comparing the level of haemoglobin in the sample to a reference level of haemoglobin, wherein a lower level of platelets and higher level of haemoglobin in the sample correlates with increased benefit to the patient.. .
Oxford Biomedica (uk) Limited


Toothpaste for delivery of allergens to oral mucosa


Pro-toothpaste compositions formulated to receive a volume of allergen solution to provide toothpastes that exhibit efficacy for oral mucosal immunotherapy (omit) and acceptable consumer and product stability properties, along with kits of pro-toothpaste, allergen/extracts of allergens, and optionally compounding means and/or specialized toothbrushes are provided. Toothpastes suitable and effective for omit and methods for managing allergic symptoms and for reducing risk of allergy in people without symptoms employing the pro-toothpastes, toothpastes and kits of the invention are also disclosed..
Allovate, Llc


Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit)


The present invention provides in vitro and in vivo diagnostic tests and methods for determining the safety, efficacy, or outcome of allergen-specific immunotherapy (sit) in a patient. The present invention also provides for the measurement of allergen specific igg and ige in a patient tissue sample, or extract thereof, or in a biological fluid or blood sample, and determining whether the allergen-specific immunoglobulins contained in the patient sample(s), upon injection into an allergen-sensitized animal, will protect the animal following challenge with the allergen.
Regeneron Pharmaceuticals, Inc.


Compounds and methods for diagnosis and immunotherapy of tuberculosis


Compounds and methods for diagnosing tuberculosis or for inducing protective immunity against tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more mycobacterium proteins and dna molecules encoding such polypeptides.
Corixa Corpoation


Methods of using recombinant listeria vaccine strains in disease immunotherapy


The present disclosure provides methods of treating, protecting against, enhancing and inducing an immune response against a tumor or cancer, comprising the step of administering to a subject a recombinant listeria. In other embodiments, the listeria stimulates the sting pathway..
Advaxis, Inc.


Cd137 enrichment for efficient tumor infiltrating lymphocyte selection


The invention includes compositions and methods to rapidly isolate and culture cells that are potent for use in adoptive immunotherapy. In one embodiment, the isolated cells of the invention are tumor infiltrating lymphocytes (til) that express cd137 (also known as 4-1bb and tnfsfr9)..
The Trustees Of The University Of Pennsylvania


Influenza nucleoprotein vaccines


The present invention is related to a fusion protein comprising a variant of a nucleoprotein antigen from influenza strain a, b or c, and a variant of a c4bp oligomerization domain for increasing the cellular immunogenicity of the nucleoprotein antigen from influenza. The invention is also related to nucleic acids, vectors, fusion proteins and immunogenic compositions, for their use as a vaccine or immunotherapy for the prevention and treatment of influenza disease..
Imaxio


Carbon nanotube compositions and methods of use thereof


Carbon nanotube (cnt)-based compositions for activating cellular immune responses are provided. The cnts function as high surface area scaffolds for the attachment of t cell ligands and/or antigens.
Yale University


Cancer immunotherapy


Methods of providing populations of nkt and/or γδ t cells, and their use, e.g., in therapies such as cancer immunotherapy.. .
University Of Massachusetts


Phl p 5a derivatives having reduced allergeneity and retained t-cell reactivity


The present invention relates to the preparation and use of variants of the group 5 allergen of the pooideae which are characterised by reduced ige reactivity compared with the known wild-type allergens and at the same time by substantially retained reactivity with t lymphocytes. These hypoallergenic allergen variants can be employed for the specific immunotherapy (hyposensitisation) of patients having grass pollen allergy or for the preventative immunotherapy of grass pollen allergies..
Merck Patent Gmbh


Immunotherapy


The invention provides an agent comprising: a cyclic peptide comprising a t cell antigen peptide; wherein in cyclised form the t cell antigen peptide is not capable of eliciting a t cell response; and wherein the t cell antigen peptide is rendered capable of eliciting a t cell response by selective cleavage of one or more cleavage sites in the cyclic peptide. The agent may be used to prevent or treat a condition characterised by the presence of unwanted cells..
The University Of Birmingham


Compositions for liquidation of tumors


This invention relates to compositions and methods for immunotherapy of cancer. Specifically, a method of cancer immunotherapy is described which results in the systemic liquidation of both solid and metastatic tumors whereever they reside in the body.
Immunovative Therapies, Ltd.


Cell-penetrating bacterial e3-ubiqitin-ligases for use in immunotherapy


The present invention relates to cell-penetrating effector proteins of type iii secretion system (t3ss)-containing bacteria of the genus salmonella or shigella and variants, fragments and immunmodulatory domains thereof, for use in immunotherapy. The present invention further relates to cell-penetrating effector proteins of type iii secretion system (t3ss)-containing bacteria of the genus salmonella or shigella and variants, fragments and immunmodulatory domains thereof, for delivering cargo molecules into eukaryotic cells..
Westfaelische Wilhelms-universitaet Muenster


Factors


A method for determining a prognosis for benefit for a cancer patient receiving immunotherapy treatment involving (a) measuring a level of haematocrit and haemoglobin in a sample from the cancer patient, and (b) comparing the level of haematocrit in the sample to a reference level of platelets and comparing the level of haemoglobin in the sample to a reference level of haemoglobin, wherein a lower level of haematocrit and higher level of haemoglobin in the sample correlates with increased benefit to the patient.. .
Oxford Biomedica (uk) Limited


Methods of identifying and treating poor prognosis cancers


The present invention relates generally to methods for identifying cancer patients with a poor prognosis, and to therapeutic modalities for improving prognosis by combating metastasis and abrogating chemoresistance in cancer cells. Embodiments of the present invention provide an objective means of prognostication regarding the long-term outcome of an incident of cancer, breast cancer in particular.
The Trustees Of Princeton University


Order a batch download of a huge number of patent PDFs. Bulk PDF Downloads This is a premium service.

Bispecific cd33 and cd3 binding proteins


Described herein are binding proteins that specifically bind to human cd33, and in particular to bispecific binding proteins that specifically bind to human cd33 and human cd3. Also described herein are bispecific tandem diabodies that bind to cd33 and cd33, and their uses for immunotherapy of cd33+ cancers, diseases and conditions such as acute myeloid leukemia (aml)..
Amphivena Therapeutics, Inc.


Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system


The present invention relates to methods of developing genetically engineered, preferably non-alloreactive t-cells for immunotherapy. This method involves the use of rna-guided endonucleases, in particular cas9/crispr system, to specifically target a selection of key genes in t-cells.

Partial region polypeptide of reic/dkk-3 protein


A polypeptide capable of strongly inducing and activating dendritic-cell-like cells for treating or prevent cancer by immunotherapy, and dna encoding the polypeptide. The polypeptide is a polypeptide (a) or (b) consisting of a partial region of the reic/dkk-3 protein..

Immunotherapy composition and use thereof


The present invention relates to the field of preventing or reducing incidence or severity of an allergic immune response, and compositions for preventing or reducing incidence or severity of an allergic immune response. For example, the present invention provides compositions comprising inactivated and/or killed cells of helicobacter pylori or a cell lysate thereof and methods and/or uses thereof for delaying or preventing or interrupting or slowing onset of one or more allergic conditions in a subject..

Allogeneic tumor cell vaccination


The present invention relates to cancer immunotherapy, specifically to allogeneic tumor cell vaccines. According to some embodiments, the invention provides novel cell lines useful as therapeutic cell vaccine compositions.

Preparation of orally administrable pharmaceutical composition containing traditional chinese medicine for hematologic diseases


Preparation of an orally administrable pharmaceutical composition containing traditional chinese medicine for hematologic diseases is disclosed. The pharmaceutical composition is for immunotherapy and is made from natural, non-toxic medicinal materials through extraction and other preparing processes.

Novel immunotherapy against neuronal and brain tumors


The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.

Method for prognosis of the efficacy of oral immunotherapy for the treatment of allergy to proteins in cow's milk


The present invention relates to a method for prognosis of the efficacy of oral immunotherapy for the treatment of allergy to proteins in cow's milk providing a solution to the problems stated in the state of the art since it provides a method which allows making a prognosis of the number of reactions that will be produced during oral immunotherapy (oit) against proteins in cow's milk and/or an estimate of the treatment time required to achieve tolerance or desensitization during oit against proteins in cow's milk and/or the need for pre-medication during oit in a human subject.. .
Fundación Para La Investigación Biomédica Del Hospital Clinico San Carlos


Human anti-sod1 antibodies


Provided are novel human copper-zinc superoxide dismutase, also known as superoxide dismutase 1 or sod1, specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for sod1 are also disclosed.
University Of Zurich


Immunotherapy against several tumors, such as lung cancer, including nsclc


The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh


Method for cancer immunotherapy


Wherein x is a tyrosine residue or a methionine residue; y and z each are a single bond or the like; r1 is a hydrogen atom or the like; r2 is a hydroxy group or the like; r3 is a hydrogen atom, alkyl group, amino group or the like; r4 is a hydrogen atom, alkyl group, carboxy group or the like; m is 1 or 2; and n is an integer of 0 to 2, with the proviso that when n is 0, r3 is a hydrogen atom or an alkyl group, or a pharmaceutically acceptable salt thereof, and its use in cancer immunotherapy.. .

Adjuvant immunotherapy for the treatment cancer, of clinical manifestations associated with the diseases like cachexia and correction of adverse effects of drugs such as immunosuppression, secundary cachexia, neutropenia and lymphopenia, comprising the association or combination of a biological response modifier specially selected and other substances with antineoplastic action and/or other treatments


A compound for use in a method of treatment of cancer, including precancerous lesions, and adverse events caused by the disease or anti-cancer agents and treatments, such as cancer cachexia, lymphopenia, neutropenia, febrile neutropenia includes in combination an immunomodulatory and at least one anti-cancer agent or treatment suitable for treating the disease. The immunomodulator is a proteic aggregate of ammonium and magnesium phospholinoleate-palmitoleate anhydride.

System for immunotherapy targeting tumor propagation and progression


Finding biologically relevant cancer markers is key to developing an effective treatment. Once specific antigens have been identified that are present on the cell population responsible for propagating tumors, t cells can be genetically altered to target these antigens and then used for personalized t cell therapy.
Verik Bio, Inc.


Immunotherapy using stem cells


Provided herein are cells, compositions and a method to produce in vitro programmed immune stimulating cells comprising: a) obtaining adipose cells from a subject; b) expanding said cells from step a) in culture so as to yield one or more populations of stem cells; c) differentiating said stem cells from step b) into hematopoetic stem cells, mesenchymal stem cells, connective cells, endothelial cells, cardio cells, osteo cells, muscle, cells and/or soft muscle tissue cells; and d) exposing said differentiated cells from step c) to 3d/4d printed molds of preselected bacterial, virus or particles thereof or exposing said differentiated cells from step c) to bacterial, virus or particles thereof so as to generate immune response triggering surface antigen expression in said differentiated cells from step c), thereby yielding in vitro programmed immune stimulating cells.. .
White Oak Industries Inc.


Immunotherapy and diagnosis of mucormycosis using coth


The invention provided mucorales coth antibodies, polypeptides, encoding nucleic acid molecules, and uses thereof. The mucorales coth antibodies, polypeptides and encoding nucleic acids disclosed herein can be advantageously used to diagnose, treat or prevent fungal conditions, in particular mucormycosis..
Los Angeles Biomedical Research Institute Harbor-ucla Medical Center


Human application of engineered chimeric antigen receptor (car) t-cells


The present invention concerns methods and compositions for immunotherapy employing a modified t cell comprising a chimeric antigen receptor (car). In particular aspects, car-expressing t-cells are producing using electroporation in conjunction with a transposon-based integration system to produce a population of car-expressing cells that require minimal ex vivo expansion or that can be directly administered to patients for disease (e.g., cancer) treatment..
Board Of Regents, The University Of Texas System


Vaccines using high-dose cytokines


The present invention relates to the field of cancer immunotherapy. In particular, vaccines are administered in conjunction with high doses of cytokines to enhance an anti-tumor immune response..
Sunnybrook And Women's College Health Sciences Center


Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases


The invention provides a system that comprises pharmaceutical agents for use in immunotherapy for reducing the side-effects of an antigen-recognizing receptor against antigen-expressing non-target cells in an individual. The system includes an antigen-recognizing receptor that specifically recognizes an antigen on target cells and at least on one hematopoietic cell type in the individual.
Miltenyi Biotec Gmbh


Ablative immunotherapy


The invention disclosed herein relates generally to immunotherapy and, more specifically, to the use of immunotherapy for treating tumors and pathogen infected tissues by first priming patients with allogeneic cells designed to be rejected by a th1 mediated mechanism, then inducing necrosis or apoptosis in a tumor or pathogen infected lesion by methods such as cryotherapy, irreversible electroporation, chemotherapy, radiation therapy, ultrasound therapy, ethanol chemoablation, microwave thermal ablation, radiofrequency energy or a combination thereof applied against at least a portion of the tumor or pathogen infected tissue, and then delivering one or more doses of allogeneic cells (e.g., th1 cells) within or proximate to the tumor or pathogen-infected tissue in the primed patient. The present invention provides an immunotherapeutic strategy to develop de-novo systemic (adaptive) immunity to a tumor or pathogen..
Immunovative Therapies, Ltd.


Ablative immunotherapy


The invention disclosed herein relates generally to immunotherapy and, more specifically, to the use of immunotherapy for treating tumors and pathogen infected tissues by first priming patients with allogeneic cells designed to be rejected by a th1 mediated mechanism, then inducing necrosis or apoptosis in a tumor or pathogen infected lesion by methods such as cryotherapy, irreversible electroporation, chemotherapy, radiation therapy, ultrasound therapy, ethanol chemoablation, microwave thermal ablation, radiofrequency energy or a combination thereof applied against at least a portion of the tumor or pathogen infected tissue, and then delivering one or more doses of allogeneic cells (e.g., th1 cells) within or proximate to the tumor or pathogen-infected tissue in the primed patient. The present invention provides an immunotherapeutic strategy to develop de-novo systemic (adaptive) immunity to a tumor or pathogen..
Immunovative Therapies, Ltd.


Order a batch download of a huge number of patent PDFs. Bulk PDF Downloads This is a premium service.

Pharmaceutical composition for viral immunotherapy and uses thereof


The present disclosure relates to a method of overcoming host immune tolerance in a subject having chronic hepatitis b virus (hbv) infection, comprising administering to the subject an immunomodulatory agent and a recombinant hbv vaccine, such that the immune tolerance of the chronic hbv infection in the subject is overcome. Moreover, the present disclosure relates to a method of treating chronic hbv infection in a subject in need thereof, comprising administering to the subject a first anti-viral agent, an immunomodulatory agent and a recombinant hepatitis b vaccine, such that the hbv infection in the subject is treated..
Fudan University


Il-12 immunotherapy for cancer


Compositions and methods for delivering immune modulatory molecules to result in a therapeutic effect are disclosed. The compositions and methods use stably integrating lentiviral delivery systems.
University Health Network


Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy


Described herein are compositions and methods of use of radionuclide-antibody conjugates (for rait) and drug-antibody conjugates (adc). The combination of rait and adc was more efficacious than either rait alone, adc alone, or the sum of effects of rait and adc.
Immunomedics, Inc.


Compositions and methods for immunotherapy


The present invention provides compositions and methods for immunotherapy, which include shelf-stable pharmaceutical compositions for inducing antigen-specific t cells. Such compositions are employed as components of an artificial antigen presenting cell (aapc), to provide a patient with complexes for presentation of an antigen (e.g., a tumor antigen) and/or a t cell co-stimulatory molecule..
Nexlmmune, Inc.


Methods and compositions for reducing immunosupression by tumor cells


The present disclosure provides, in part, methods of discovering immunotherapy targets in vivo, therapeutic compositions (e.g., shrna, immunoresponsive cells expressing shrna and/or a chimeric antigen receptors (car)), and methods of use thereof.. .
The General Hospital Corporation D/b/a Massachusetts General Hospital


Composition comprised of antigen linked to a tnf superfamily ligand


The invention provides fusion proteins comprising antigens of infectious disease agents and cancer cells linked to multiple-trimer forms of tnf superfamily (tnfsf) ligands. The tnfsfs serve as vaccine adjuvants for increasing the immune response to the antigens.

Biological markers useful in cancer immunotherapy


Methods are disclosed that are based on the finding that serum and plasma levels of eotaxin, mip1α, and crp act as important biomarkers that are useful for determining the feasibility in instigating immunotherapeutic treatment of cancer when immunizing with the gv1001 peptide (earpalltsrlrfipk; derived from human telomerase protein), optionally when combined with state of the art combination treatment with gemcitabine and capecitabine. In particular, the present invention provides methods for determining whether patients should be treated gv1001 and for determining whether instigated treatment should be continued..
Gemvax & Kael Co., Ltd.


Uses of il-12 in hematopoietic immunotherapy (hit)


Aspects and embodiments of the instant disclosure provide therapeutic methods and compositions comprising interleukin 12 (il-12) as a hematopoietic immunotherapy (hit) useful for treating or preventing a cancer patient from chemotherapy-induced cytopenias necessitating a dose reduction and/or dose delay. Following exposure of the patient to chemotherapeutic agents, the method comprising: administering a dose of therapeutically effective amount of a pharmaceutical composition comprising substantially isolated il-12 to the subject, whereby cytopenias are reduced and leading to increases responses to the chemotherapy agent(s).diminished..
Neumedicines, Inc.


Methods for engineering highly active t cell for immunotheraphy


The present invention relates to methods for developing engineered t-cells for immunotherapy and more specifically to methods for modifying t-cells by inactivating at immune checkpoint genes, preferably at least two selected from different pathways, to increase t-cell immune activity. This method involves the use of specific rare cutting endonucleases, in particular tale-nucleases (tal effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in t-cells, which are available from donors or from culture of primary cells.
Cellectis


Methods for engineering allogeneic and highly active t cell for immunotheraphy


The present invention relates to methods for developing engineered t-cells for immunotherapy that are non-alloreactive. The present invention relates to methods for modifying t-cells by inactivating both genes encoding t-cell receptor and an immune checkpoint gene to unleash the potential of the immune response.
Cellectis


Tumor-associated peptides binding promiscuously to human leukocyte antigen (hla) class ii molecules


The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh


Antioxidant, anti-inflammatory and anticancer derivatives of triptolide and nanospheres thereof


This invention relates to uses of conjugates of triptolide nanoprodrugs in cancer immunotherapy, specifically compound such as d-i or d-ii wherein x1 is a antioxidant, an anti-inflammatory or an anti-cancer agent and nanospheres thereof, and a is be selected from the group consisting of branched and unbranched alkyl, branched and unbranched alkenyl, branched and unbranched alkynyl, heteroatom-containing branched and unbranched alkyl, heteroatom-containing branched and unbranched alkenyl, heteroatom-containing branched and unbranched alkynyl, aryl, cyclic aliphatic, cyclic aromatic, heterocyclic, and aromatic heterocyclic groups.. .
Cedars-sinai Medical Center


Chelates of lead (ii) and bismuth (iii) based on trans-di-n-picolinate tetraazacycloalkanes


The invention relates to a chelate resulting from the complexing of a trans-di-n-picolinate tetraazacycloalkane ligand with a metal cation, said ligand corresponding to formula (a) wherein n is equal to 0 or to 1, r is h or a c1-c18 alkyl radical, and r′ is h or a c1 -c18 alkyl radical, said metal cation being a cation of a metal selected from the group consisting of lead (ii) and bismuth (iii). The invention is applicable in the field of lead trapping and alpha-radioimmunotherapy..
Universite De Bretagne Occidentale


Imp-3 epitope peptides for th1 cells and vaccines containing the same


Isolated imp-3-derived epitope peptides having th1 cell inducibility are disclosed herein. Such peptides can be recognized by mhc class ii molecules and induce th1 cells.
Oncotherapy Science, Inc.


Compositions and methods for immunotherapy


The present invention provides novel immunotherapeutic compositions and methods useful for treating or preventing microbial infections, weakened immune systems, diseases in which cells have become obligately anerobic and cellular proliferative disorders including cancer. The immunotherapeutics herein use benzaldehyde derivatives, precursors and intermediaries alone or in combination with additional therapeutic agents to stimulate the immune system and inhibit cellular proliferation.

Re-directed immunotherapy


The invention provides an agent for preventing or treating a condition characterised by the presence of unwanted cells, the agent comprising: (i) a targeting moiety that is capable of targeting to the unwanted cells; and (ii) a t cell antigen, wherein the t cell antigen can be released from the targeting moiety by selective cleavage of a cleavage site in the agent in the vicinity of the unwanted cells.. .

Immunotherapy using a logical and combination for immune response activation


A method for treating a malignant tumor in a patient identifies tumor cells using a logical and operation on antigens on the surfaces of the tumor cells. First and second antigens are determined to be present on the tumor cells.

Anti-measles cancer immunotherapy


The present invention provides methods for treating specific populations of cancer patients by immunotherapy. The methods comprise administering an immunogenic composition eliciting an immune response to measles virus to patients having measles virus-immunoreactive cancer cells..

Vmp-like sequences of pathogenic borrelia species and strains


The present invention relates to dna sequences encoding vmp-like polypeptides of pathogenic borrelia, the use of the dna sequences in recombinant vectors to express polypeptides, the encoded amino acid sequences, application of the dna and amino acid sequences to the production of polypeptides as antigens for immunoprophylaxis, immunotherapy, and immunodiagnosis. Also disclosed are the use of the nucleic acid sequences as probes or primers for the detection of organisms causing lyme disease, relapsing fever, or related disorders, and kits designed to facilitate methods of using the described polypeptides, dna segments and antibodies..

Neoadjuvant use of antibody-drug conjugates


The present invention concerns improved methods and compositions for neoadjuvant use of antibody-drug conjugates (adcs) in cancer therapy, preferably adcs comprising an anthracycline or camptothecin, more preferably sn-38 or pro-2-pyrrolinodoxorubicin (p2pdox). The adc is administered as a neoadjuvant, prior to treatment with a standard anti-cancer therapy such as surgery, radiation therapy, chemotherapy, or immunotherapy.
Immunomedics, Inc.


Allergen peptide fragments and use thereof for treatment of birch pollen allergies


The present invention relates generally to in vivo methods and compositions designed for allergen specific immunotherapy. The compositions include contiguous overlapping peptide fragments which together form an entire amino acid sequence of an allergen..
Anergis S.a.


Method for the treatment of obesity


The present invention relates to therapeutic compositions for treating or preventing obesity and obesity-related disorders in a subject using immunotherapy to target and eliminate adipocytes.. .
Fred Hutchinson Cancer Research Center


Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity


The present invention relates to therapeutic immunoconjugates comprising sn-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to egp-1 (trop-2), ceacam5, ceacam6, cd74, cd19, cd20, cd22, csap, hla-dr, afp or muc5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg.
Immunomedics, Inc.


Cancer immunotherapy by disrupting pd-1/pd-l1 signaling


The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the pd-1/pd-l1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express pd-l1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-pd-1 antibody to the selected subject.
Bristol-myers Squibb Company




Immunotherapy topics:
  • Immunotherapy
  • Therapeutics
  • Antibodies
  • Immune Response
  • Monoclonal
  • Monoclonal Antibody
  • Stimulator
  • Immunostimulator
  • Compatibility
  • Histocompatibility
  • Specificity
  • Major Histocompatibility Complex
  • Radiation Therapy
  • Treatments
  • Amino Acid


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Immunotherapy for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immunotherapy with additional patents listed. Browse our RSS directory or Search for other possible listings.


    1.0242

    5110

    0 - 1 - 102